Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.9K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.9K
Drug Discovery: Overview01:26

Drug Discovery: Overview

12.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
12.2K
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

34
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
34
Pharmacodynamic Models: Overview01:27

Pharmacodynamic Models: Overview

23
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
23
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

27
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
27
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

2.3K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
2.3K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

An H3K18la-ALKBH5-Runx2-LDHA positive feedback loop promotes vascular calcification in the osteogenic phenotypic transition of vascular smooth muscle cells.

Cellular signalling·2026
Same author

Factors Associated With Hyperuricemia in Patients With Coronary Heart Disease.

Reviews in cardiovascular medicine·2026
Same author

GluD1 is localized at cholinergic synapses and is an acetylcholine receptor.

Molecular psychiatry·2026
Same author

A Molecular Playground for Spin-State Ice and Coupled Electron-Spin Dynamics.

Journal of the American Chemical Society·2026
Same author

Three-dimensional printing of multilayer stretchable electronics with inclined interconnect accesses.

Nature communications·2026
Same author

Development and validation of a machine learning-based model for assessing coronary artery disease risk in postmenopausal women: a dual-center retrospective study.

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2026

関連する実験動画

Updated: Feb 24, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K

Assay2Mol：生体分析コンテキストを用いた大規模言語モデルベースの創薬

Yifan Deng1,2, Spencer S Ericksen3, Anthony Gitter1,2,4

  • 1Department of Computer Sciences, University of Wisconsin-Madison.

Proceedings of the Conference on Empirical Methods in Natural Language Processing. Conference on Empirical Methods in Natural Language Processing
|February 23, 2026
PubMed
まとめ
この要約は機械生成です。

Assay2Molは、既存のバイオアッセイ情報を学習することで新規薬剤候補を生成し、他の手法を上回る性能を発揮する創薬のための新しいワークフローです。

キーワード:
創薬大規模言語モデル生化学的スクリーニング分子生成コンテキスト学習

さらに関連する動画

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.7K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K

関連する実験動画

Last Updated: Feb 24, 2026

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.6K
Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
05:50

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro

Published on: September 26, 2025

1.7K
Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
06:26

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery

Published on: May 16, 2021

5.6K

科学分野:

  • 生化学
  • 計算論的創薬
  • バイオインフォマティクス

背景:

  • 科学データベースには、膨大な定量的およびテキストデータが含まれています。
  • 生化学的アッセイは、疾患標的を対象とした分子をスクリーニングします。
  • アッセイの非構造化テキストには、貴重な創薬情報が含まれています。
  • この情報は、その形式のためにほとんど活用されていません。

研究 の 目的:

  • Assay2Mol、大規模言語モデルベースのワークフローを提示すること。
  • 既存の生化学的スクリーニングアッセイを初期段階の創薬に活用すること。
  • 構造化されていないアッセイデータの可能性を解き放つこと。

主な方法:

  • Assay2Molは大規模言語モデルを利用しています。
  • 類似の標的に対する既存のアッセイ記録を取得します。
  • 取得したデータからのコンテキスト内学習を使用して候補分子を生成します。

主要な成果:

  • Assay2Molは最近の機械学習アプローチよりも優れた性能を発揮します。
  • 標的タンパク質構造に対する候補リガンド分子を効果的に生成します。
  • このワークフローは、より合成可能な分子の生成を促進します。

結論:

  • Assay2Molは、既存の生化学的スクリーニングアッセイを活用しています。
  • 初期段階の創薬のための新しいアプローチを提供します。
  • この方法は、実行可能な創薬候補の生成を強化します。